Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: A biotech's challenge

Biotechnology Advances

Volumn 30, Issue 1, 2012, Pages 372-383

  Iurescia, Sandra ^a   Fioretti, Daniela ^a   Fazio, Vito Michele ^b   Rinaldi, Monica ^a  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Active immunotherapy; Biopharmaceuticals; Biotechnology; Cancer vaccine; DNA vaccination; Epitope prediction; Immunoinformatics; Innovative medicine; Patient specific vaccine; Tailored drug

Indexed keywords

ACTIVE IMMUNOTHERAPY; BIOPHARMACEUTICALS; CANCER VACCINE; DNA VACCINATION; EPITOPE-PREDICTION; IMMUNOINFORMATICS; TAILORED DRUG;

ANTIGENS; BIOINFORMATICS; BIOTECHNOLOGY; CELLS; DESIGN; DISEASES; DNA; FORECASTING; GENES; MOLECULAR BIOLOGY; ONCOLOGY; POLYPEPTIDES; TUMORS;

VACCINES;

DNA VACCINE; EPITOPE;

ADVANCED TECHNOLOGY; BIOINFORMATICS; BIOTECHNOLOGY; CANCER; CELL ORGANELLE; COMPUTER SIMULATION; DISEASE TREATMENT; DNA; DRUG; GENE EXPRESSION; GENETIC ANALYSIS; MOLECULAR ANALYSIS; VACCINATION;

ANIMAL; B CELL LYMPHOMA; BIOLOGY; HUMAN; IMMUNOLOGY; MOUSE; REVIEW;

ANIMALS; COMPUTATIONAL BIOLOGY; EPITOPES, T-LYMPHOCYTE; HUMANS; LYMPHOMA, B-CELL; MICE; VACCINES, DNA;

EID: 84855735425     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.06.020     Document Type: Review

References (115)

1. Altuvia Y., Margalit H. Sequence signals for generation of antigenic peptides by the proteasome: implications for proteasomal cleavage mechanism. J Mol Biol 2000, 295:879-890.
2. Alvarez-Salas L.M. Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia. Curr Opin Mol Ther 2008, 10:622-628.
3. Anderson R., Gao X.M., Papakonstantinopoulou A., Fairweather N., Roberts M., Dougan G. Immunization of mice with DNA encoding fragment C of tetanus toxin. Vaccine 1997, 15:827-829.
4. Borbulevych O.Y., Baxter T.K., Yu Z., Restifo N.P., Baker B.M. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol 2005, 174:4812-4820.
5. Brown E.L., Wooters J.L., Ferenz C.R., O'Brien C.M., Hewick R.M., Herrmann S.H. Characterization of peptide binding to the murine MHC class I H-2Kk molecule. Sequencing of the bound peptides and direct binding of synthetic peptides to isolated class I molecules. J Immunol 1994, 153:3079-3092.
6. Campbell M.J., Carroll W., Kon S., Thielemans K., Rothbard J.B., Levy S., et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987, 139:2825-2833.
7. Chen W., McCluskey J. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer Res 2006, 95:203-247.
8. Cox G.J., Zamb T.J., Babiuk L.A. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J Virol 1993, 67:5664-5667.
9. Delogu G., Howard A., Collins F.M., Morris S.L. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 2000, 68:3097-3102.
10. Deluca D.S., Blasczyk R. The immunoinformatics of cancer immunotherapy. Tissue Antigens 2007, 70:265-271.
11. Demotz S., Barbey C., Corradin G., Amoroso A., Lanzavecchia A. The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur J Immunol 1993, 23:425-432.
12. Egan A.F., Blackman M.J., Kaslow D.C. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys. Infect Immun 2000, 68:1418-1427.
13. EMEA Guideline on non-clinical studies required before first clinical use of gene therapy medicinal product 2006.
14. Fairweather N.F., Lyness V.A., Pickard D.J., Allen G., Thomson R.O. Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli. J Bacteriol 1986, 165:21-27.
15. FDA Guidance for industry: considerations for plasmid DNA vaccines for infectious disease indications 2007, US Food and Drug Administration.
16. Fioretti D., Iurescia S., Fazio V.M., Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010, 2010:174378.
17. Gerber L.D., Kodukula K., Udenfriend S. Phosphatidylinositol glycan (PI-G) anchored membrane proteins. Amino acid requirements adjacent to the site of cleavage and PI-G attachment in the COOH-terminal signal peptide. J Biol Chem 1992, 267:12168-12173.
18. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899.
19. Hakim I., Levy S., Levy R. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996, 157:5503-5511.
20. Hammer J., Bono E., Gallazzi F., Belunis C., Nagy Z., Sinigaglia F. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 1994, 180:2353-2358.
21. Hansson L., Rabbani H., Fagerberg J., Osterborg A., Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 2003, 101:4930-4936.
22. Harig S., Witzens M., Krackhardt A.M., Trojan A., Barrett P., Broderick R., et al. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood 2001, 98:2999-3005.
23. Hoof I., Peters B., Sidney J., Pedersen L.E., Sette A., Lund O., et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009, 61:1-13.
24. Houot R., Levy R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 2009, 23:137-142.
25. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998, 188:2357-2368.
26. Iurescia S., Fioretti D., Pierimarchi P., Signori E., Zonfrillo M., Fazio V.M., et al. DNA vaccines for B-cell lymphomas: towards personalised medicine and tailored drugs. J Biotechnol 2010, 150(Supplement 1):99-100.
27. Iurescia S., Fioretti D., Pierimarchi P., Signori E., Zonfrillo M., Tonon G., et al. Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma. J Biomed Biotechnol 2010, 2010:316069.
28. James E.A., Bui J., Berger D., Huston L., Roti M., Kwok W.W. Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int Immunol 2007, 19:1291-1301.
29. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421:852-856.
30. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S., et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995, 154:3961-3968.
31. Kessler B.M., Bassanini P., Cerottini J.C., Luescher I.F. Effects of epitope modification on T cell receptor-ligand binding and antigen recognition by seven H-2Kd-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. J Exp Med 1997, 185:629-640.
32. Kim Y., Sette A., Peters B. Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource. J Immunol Methods 2011, 374:62-69.
33. King C.A., Spellerberg M.B., Zhu D., Rice J., Sahota S.S., Thompsett A.R., et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998, 4:1281-1286.
34. Klencke B., Matijevic M., Urban R.G., Lathey J.L., Hedley M.L., Berry M., et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002, 8:1028-1037.
35. Kobayashi H., Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol 2008, 20:221-227.
36. Korber B., LaBute M., Yusim K. Immunoinformatics comes of age. PLoS Comput Biol 2006, 2:e71.
37. Larsen M.V., Lundegaard C., Lamberth K., Buus S., Brunak S., Lund O., et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 2005, 35:2295-2303.
38. Le T.P., Coonan K.M., Hedstrom R.C., Charoenvit Y., Sedegah M., Epstein J.E., et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000, 18:1893-1901.
39. Ledwith B.J., Manam S., Troilo P.J., Barnum A.B., Pauley C.J., Griffiths T.G., et al. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 2000, 43:258-272.
40. Lee E.A., Palmer D.R., Flanagan K.L., Reece W.H., Odhiambo K., Marsh K., et al. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun 2002, 70:1417-1421.
41. Lefranc M.P. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res 2001, 29:207-209.
42. Lefranc M.P., Pommie C., Ruiz M., Giudicelli V., Foulquier E., Truong L., et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 2003, 27:55-77.
43. Leifert J.A., Rodriguez-Carreno M.P., Rodriguez F., Whitton J.L. Targeting plasmid-encoded proteins to the antigen presentation pathways. Immunol Rev 2004, 199:40-53.
44. Li Pira G., Ivaldi F., Moretti P., Manca F. High throughput T epitope mapping and vaccine development. J Biomed Biotechnol 2010, 10.1155/2010/325720.
45. Liu M.A. Gene-based vaccines: Recent developments. Curr Opin Mol Ther 2010, 12:86-93.
46. Liu M.A. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011, 239:62-84.
47. Lund L.H., Andersson K., Zuber B., Karlsson A., Engstrom G., Hinkula J., et al. Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. Cancer Gene Ther 2003, 10:365-376.
48. Lundegaard C., Lamberth K., Harndahl M., Buus S., Lund O., Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008, 36:W509-W512.
49. Lundegaard C., Hoof I., Lund O., Nielsen M. State of the art and challenges in sequence based T-cell epitope prediction. Immunome Res 2010, 6(Suppl 2):S3-S.
50. Lundegaard C., Lund O., Buus S., Nielsen M. Major histocompatibility complex class I binding predictions as a tool in epitope discovery. Immunology 2010, 130:309-318.
51. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998, 178:92-100.
52. Mincheff M., Tchakarov S., Zoubak S., Loukinov D., Botev C., Altankova I., et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2000, 38:208-217.
53. Murphy K.M., Travers P., Walport M. Janeway's Immunobiology 2007, Garland Science Publishing, New York. Seventh Edition.
54. Nguyen D.N., Green J.J., Chan J.M., Langer R., Anderson D.G. Polymeric Materials for Gene Delivery and DNA Vaccination. Adv Mater 2009, 21:847-867.
55. Nielsen M., Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009, 10:296.
56. Nielsen M., Lundegaard C., Blicher T., Peters B., Sette A., Justesen S., et al. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol 2008, 4:e1000107.
57. Nielsen M., Justesen S., Lund O., Lundegaard C., Buus S. NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 2010, 6:9.
58. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989, 19:2237-2242.
59. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994, 152:163-175.
60. Perales M.A., Yuan J., Powel S., Gallardo H.F., Rasalan T.S., Gonzalez C., et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 2008, 16:2022-2029.
61. Peters B., Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005, 6:132.
62. Ramanathan M.P., Ayyavoo V., Weiner D.B. Choice of expression vector alters the localization of a human cellular protein. DNA Cell Biol 2001, 20:101-105.
63. Rammensee H.G., Friede T., Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995, 41:178-228.
64. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
65. Reche P.A., Glutting J.P., Reinherz E.L. Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 2002, 63:701-709.
66. Rice J., King C.A., Spellerberg M.B., Fairweather N., Stevenson F.K. Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine 1999, 17:3030-3038.
67. Rice J., Elliott T., Buchan S., Stevenson F.K. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J Immunol 2001, 167:1558-1565.
68. Rice J., Buchan S., Stevenson F.K. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J Immunol 2002, 169:3908-3913.
69. Rice J., Ottensmeier C.H., Stevenson F.K. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008, 8:108-120.
70. Rinaldi M., Ria F., Parrella P., Signori E., Serra A., Ciafre S.A., et al. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Cancer Res 2001, 61:1555-1562.
71. Rinaldi M., Iurescia S., Fioretti D., Signori E., Tonon G., Fazio V.M. Cancer immunotherapy 2006 meets strategies for immune therapy: CDR3-targeted DNA vaccines in B-cell lymphoma. Cancer Immunol Immunother 2007, 56:403-427.
72. Rinaldi M., Fioretti D., Iurescia S., Signori E., Pierimarchi P., Seripa D., et al. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. Biochem Biophys Res Commun 2008, 370:279-284.
73. Rosa D.S., Ribeiro S.P., Cunha-Neto E. CD4+ T cell epitope discovery and rational vaccine design. Arch Immunol Ther Exp 2010, 58:121-130.
74. Rotzschke O., Falk K., Stevanovic S., Jung G., Walden P., Rammensee H.G. Exact prediction of a natural T cell epitope. Eur J Immunol 1991, 21:2891-2894.
75. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000, 19:764-778.
76. Schalk J.A., Mooi F.R., Berbers G.A., van Aerts L.A., Ovelgonne H., Kimman T.G. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin 2006, 2:45-53.
77. Scholz C., Tampe R. The intracellular antigen transport machinery TAP in adaptive immunity and virus escape mechanisms. J Bioenerg Biomembr 2005, 37:509-515.
78. Sette A., Buus S., Appella E., Smith J.A., Chesnut R., Miles C., et al. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci USA 1989, 86:3296-3300.
79. Sheets R.L., Stein J., Manetz T.S., Andrews C., Bailer R., Rathmann J., et al. Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Toxicol Sci 2006, 91:620-630.
80. Sheets R.L., Stein J., Manetz T.S., Duffy C., Nason M., Andrews C., et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 2006, 91:610-619.
81. Signori E., Iurescia S., Massi E., Fioretti D., Chiarella P., De Robertis M., et al. DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunol Immunother 2010, 59:1583-1591.
82. Smith C.M., Wilson N.S., Waithman J., Villadangos J.A., Carbone F.R., Heath W.R., et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 2004, 5:1143-1148.
83. Snyder H.L., Bacik I., Yewdell J.W., Behrens T.W., Bennink J.R. Promiscuous liberation of MHC-class I-binding peptides from the C termini of membrane and soluble proteins in the secretory pathway. Eur J Immunol 1998, 28:1339-1346.
84. Spellerberg M.B., Zhu D., Thompsett A., King C.A., Hamblin T.J., Stevenson F.K. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J Immunol 1997, 159:1885-1892.
85. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368:215-221.
86. Stevenson F.K., Zhu D., King C.A., Ashworth L.J., Kumar S., Hawkins R.E. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 1995, 145:211-228.
87. Stevenson F.K., Rice J., Ottensmeier C.H., Thirdborough S.M., Zhu D. DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunol Rev 2004, 199:156-180.
88. Stranzl T., Larsen M.V., Lundegaard C., Nielsen M. NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics 2010, 62:357-368.
89. Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356:152-154.
90. Tenzer S., Peters B., Bulik S., Schoor O., Lemmel C., Schatz M.M., et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci 2005, 62:1025-1037.
91. Terasawa H., Tsang K.Y., Gulley J., Arlen P., Schlom J. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res 2002, 8:41-53.
92. Thielemans K., Rothbard J.B., Levy S., Levy R. Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens. J Exp Med 1985, 162:19-34.
93. Thirdborough S.M., Radcliffe J.N., Friedmann P.S., Stevenson F.K. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma. Cancer Res 2002, 62:1757-1760.
94. Trojan A., Schultze J.L., Witzens M., Vonderheide R.H., Ladetto M., Donovan J.W., et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000, 6:667-672.
95. Tsang K.Y., Palena C., Gulley J., Arlen P., Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 2004, 10:2139-2149.
96. Tymciu S., Durieux-Alexandrenne C., Wijkhuisen A., Creminon C., Frobert Y., Grassi J., et al. Enhancement of antibody responses in DNA vaccination using a vector encoding a universal T-helper cell epitope. DNA Cell Biol 2004, 23:395-402.
97. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
98. Ulmer J.B., Deck R.R., Dewitt C.M., Donnhly J.I., Liu M.A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996, 89:59-67.
99. Valmori D., Fonteneau J.F., Lizana C.M., Gervois N., Lienard D., Rimoldi D., et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998, 160:1750-1758.
100. Velders M.P., Weijzen S., Eiben G.L., Elmishad A.G., Kloetzel P.M., Higgins T., et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 2001, 166:5366-5373.
101. Vita R., Zarebski L., Greenbaum J.A., Emami H., Hoof I., Salimi N., et al. The immune epitope database 2.0. Nucleic Acids Res 2010, 38:D854-D862.
102. Wan Y.Y., Flavell R.A. How diverse-CD4 effector T cells and their functions. J Mol Cell Biol 2009, 1:20-36.
103. Wang P., Sidney J., Dow C., Mothe B., Sette A., Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008, 4:e1000048.
104. Weber J., Boswell W., Smith J., Hersh E., Snively J., Diaz M., et al. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008, 31:215-223.
105. Weiss R., Durnberger J., Mostbock S., Scheiblhofer S., Hartl A., Breitenbach M., et al. Improvement of the immune response against plasmid DNA encoding OspC of Borrelia by an ER-targeting leader sequence. Vaccine 1999, 18:815-824.
106. Williams B.B., Wall M., Miao R.Y., Williams B., Bertoncello I., Kershaw M.H., et al. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. Cancer Immunol Immunother 2008, 57:1635-1645.
107. Williams J.A., Carnes A.E., Hodgson C.P. Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production. Biotechnol Adv 2009, 27:353-370.
108. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247:1465-1468.
109. Xu W., Chu Y., Zhang R., Xu H., Wang Y., Xiong S. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine. Virology 2005, 334:255-263.
110. Yewdell J.W., Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999, 17:51-88.
111. Zaremba S., Barzaga E., Zhu M., Soares N., Tsang K.Y., Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997, 57:4570-4577.
112. Zhang H., Lundegaard C., Nielsen M. Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods. Bioinformatics (Oxford, England) 2009, 25:83-89.
113. Zhang G.L., Deluca D.S., Keskin D.B., Chitkushev L., Zlateva T., Lund O., et al. MULTIPRED2: A computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles. J Immunol Methods 2011, 374:53-61.
114. Zinckgraf J.W., Silbart L.K. Modulating gene expression using DNA vaccines with different 3'-UTRs influences antibody titer, seroconversion and cytokine profiles. Vaccine 2003, 21:1640-1649.
115. Zinkernagel R.M. Uncertainties - discrepancies in immunology. Immunol Rev 2002, 185:103-125.